PharmaLogic Successfully Delivers First Dose for Novel Radiopharmaceutical in Sarcoma Study PharmaLogic Holdings has successfully supplied initial doses of an innovative FAP-targeted radiopharmaceutical for the ATLAS trial, aiming to treat aggressive sarcomas.

PharmaLogic Successfully Delivers First Dose for Novel Radiopharmaceutical in Sarcoma Study #United_States #Bronx #PharmaLogic #Ratio_Therapeutics #Ac-225-RTX-2358

Ratio Therapeutics Advances Cancer Treatment with Successful Dosing of First Patient in Phase 1/2 Trial Ratio Therapeutics has begun its Phase 1/2 study of a new FAP-targeted drug for treating late-stage sarcomas, marking a significant milestone.

Ratio Therapeutics Advances Cancer Treatment with Successful Dosing of First Patient in Phase 1/2 Trial #United_States #Boston #Ratio_Therapeutics #FAP-targeted_drug #Ac-225-RTX-2358

Ratio Therapeutics Appoints Marcel Reichen as Chief Strategy Officer, Focusing on Radiopharmaceutical Growth Ratio Therapeutics has appointed Marcel Reichen as Chief Strategy Officer. His expertise will guide the company's expansion in radiopharmaceuticals for cancer treatment.

Ratio Therapeutics Appoints Marcel Reichen as Chief Strategy Officer, Focusing on Radiopharmaceutical Growth #USA #Boston #radiopharmaceuticals #Ratio_Therapeutics #Marcel_Reichen

Ratio Therapeutics and TerraPower Isotopes Unite for Innovative Cancer Treatment Supply Ratio Therapeutics has teamed up with TerraPower Isotopes to secure Actinium-225, a vital isotope for advancing targeted cancer therapies, enhancing treatment options significantly.

Ratio Therapeutics and TerraPower Isotopes Unite for Innovative Cancer Treatment Supply #Actinium-225 #Ratio_Therapeutics #TerraPower_Isotopes

Ratio Therapeutics and Nusano Forge Agreement for Advanced Cancer Radiopharmaceuticals Production Ratio Therapeutics and Nusano have teamed up for a significant agreement aimed at enhancing the production of advanced cancer radiopharmaceuticals. This partnership is set to boost various therapies significantly.

Ratio Therapeutics and Nusano Forge Agreement for Advanced Cancer Radiopharmaceuticals Production #United_States #Boston #radiopharmaceuticals #Nusano #Ratio_Therapeutics

Ratio Therapeutics Collaborates with Macrocyclics to Expand Cancer Treatment Access Worldwide Ratio Therapeutics has partnered with Macrocyclics for the exclusive manufacturing and distribution of its innovative cancer-treatment chelator platform, Macropa.

Ratio Therapeutics Collaborates with Macrocyclics to Expand Cancer Treatment Access Worldwide #USA #Boston #Ratio_Therapeutics #Macrocyclics #Macropa

Ratio Therapeutics Announces the Launch of New Radiopharmaceutical Manufacturing Facility in Utah Ratio Therapeutics is set to build a cutting-edge radiopharmaceutical manufacturing facility in Utah, enhancing cancer treatment capabilities.

Ratio Therapeutics Announces the Launch of New Radiopharmaceutical Manufacturing Facility in Utah #United_States #Cancer_Treatment #Salt_Lake_City #radiopharmaceuticals #Ratio_Therapeutics